Growth Opportunities and Trends in the Diabetic Gastroparesis Treatment Market: Key Insights for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the diabetic gastroparesis treatment market grown over the years?
In recent years, the diabetic gastroparesis treatment market has witnessed a consistent expansion. The market size, currently at $3.89 billion in 2024, is projected to increase to $4.07 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. This market growth throughout the historic period can be credited to the rise in diabetes incidence, a scarcity of treatment alternatives, escalating awareness and diagnostic rates, as well as the development of healthcare infrastructure.
What Is the forecasted market size and growth rate for the diabetic gastroparesis treatment market?
Anticipating robust growth in the coming years, the market size of treatments for diabetic gastroparesis is projected to expand to $5.13 billion in 2029, with a compound annual growth rate (CAGR) of 6.0%. The expansion during the forecast period may be credited to advances in precision medicine and personalized therapies, a growing diabetic demographic, heightened research and development activities, and regulatory changes. Technological advancements in treatment procedures, the introduction of innovative therapies, emphasis on symptom management, the adoption of telemedicine and remote monitoring, and interventions targeting the gut microbiome are the primary trends anticipated in the forecast duration.
Get your diabetic gastroparesis treatment market report here!
What are the major factors driving growth in the diabetic gastroparesis treatment market?
The continued rise in diabetes cases is anticipated to propel the expansion of the diabetic gastroparesis treatment market. When we talk about diabetes prevalence, we are discussing the portion or percent of the population diagnosed with diabetes at a given time. The main aim of diabetic gastroparesis treatment is to manage the symptoms and complications of this condition, a common difficulty associated with diabetes. In April 2023, a report from The British Diabetic Association, a diabetes charity based in the UK, revealed that 4.3 million UK residents are living with diabetes. Furthermore, over 2.4 million people in the UK are at a high risk of developing type 2 diabetes, and the registration numbers for 2021–22 stand at 148,951. Hence, the escalating prevalence of diabetes is fueling the expansion of the diabetic gastroparesis treatment market.
What key areas define the segmentation of the global diabetic gastroparesis treatment Market?
The diabetic gastroparesis treatment market covered in this report is segmented –
1) By Treatment: Medication, Surgery
2) By Route Of Administration: Oral, Injectables
3) By Indication: Compensated Gastroparesis, Gastric Failure
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants, Other Pharmacological Therapies
2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage, Other Surgical Interventions
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12580&type=smp
What are the top market players propelling the growth of the diabetic gastroparesis treatment industry?
Major companies operating in the diabetic gastroparesis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC
What are the key trends shaping the future of the diabetic gastroparesis treatment market?
The creation of novel medicines is an emerging trend gaining traction in the diabetic gastroparesis treatment market. Major players in this market are exploring new product development to maintain their market standing. For example, in June 2023, the US-based federal agency, The U.S. Food and Drug Administration, gave approval to two drugs that have been utilized to manage type 2 diabetes in adults, and these are now sanctioned for use in children aged ten and above. The approval of Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride) has ushered in a fresh class of drugs for treating type 2 diabetes in children. Synjardy, which is a blend of empagliflozin and metformin, is used to attain superior glycemic control in patients inflicted with type 2 diabetes. By leveraging two dissimilar action mechanisms, Synjardy can deliver more extensive blood sugar control than using either drug individually.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12580
What regions are dominating the diabetic gastroparesis treatment market growth?
North America was the largest region in the diabetic gastroparesis treatment market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Ocular Implants Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report
Diabetic Foods Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/diabetic-foods-global-market-report
Gastroparesis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
